Latest Headlines

Latest Headlines

J&J inks deal to access Nuevolution's informatics-enabled discovery platform

Johnson & Johnson has added another company to its ever-growing network of third-party drug discovery allies. The latest deal sees J&J subsidiary Janssen Biotech follow GlaxoSmithKline, Merck, Novartis and others by hooking up with Nuevolution to get a look at its drug discovery platform.

Angling for more reach with providers, Merck melds Univadis unit with Physicians Interactive

In a Merck-to-Merck transaction, multichannel healthcare marketer Physicians Interactive has acquired healthcare professional content provider and network Univadis. Univadis had previously been a wholly owned and operated subsidiary of Merck, while Physicians Interactive is a wholly owned subsidiary of Merck that operates independently with its own board of directors.

Chinese company intends to build plant to produce Ebola vax

A lot of companies, large and small, have jumped into a race to produce vaccines and treatments against the Ebola virus after an epidemic that began in 2014 killed 11,000 people in West Africa. Now a Chinese company says it will build a plant for production of a vaccine being tested by China's military.

Analysts, experts write off Merck's huge anacetrapib PhIII

Three years ago, Eli Lilly heart specialist Jeffrey Riesmeyer scoffed at the notion that the failure of CETP inhibitors at Roche and Pfizer was a bad sign for their big Phase III program for evacetrapib. Evacetrapib wound up proving that Lilly was dead wrong about its theory.

BMS' Opdivo gets a jump on Keytruda with another early FDA approval

Ready for the lung cancer showdown between Merck & Co.'s Keytruda and Bristol-Myers Squibb's Opdivo? It's here, and way ahead of schedule.

U.K. cost watchdog gives second thumbs-up in a week to Merck's Keytruda for skin cancer

Merck's Keytruda is two-for-two with the U.K.'s cost watchdog, nabbing another thumbs-up to treat skin cancer days after the National Institute of Health and Care Excellence signed off on the med for patients who have already received treatment.

Australia's Bionomics gets more cash from Merck on pain, oncology, CNS bets

Australia-listed biotech Bionomics has seen Merck expand its interest in a broad pipeline of candidates, buying nearly 5.3% of its outstanding ordinary shares at a 29% premium along with an additional $9 million investment.

Ruling on Merck diabetes drug shows domestic firms not favored in India courts

Dilip Shah, secretary-general of the Indian Pharmaceutical Alliance, said this week's decision by the Delhi High Court against homegrown Glenmark Pharmaceuticals showed "due process was followed" and that Indian companies could not count on Indian courts for special treatment, according to a report in the Wall Street Journal.

Merck notches another win in India patent battle over diabetes bestsellers

Everything is coming up roses for Merck in its patent battle with India's Glenmark Pharmaceuticals over copycats of the drugmaker's diabetes meds Januvia and Janumet, as the Delhi High Court barred the generics company from selling cheap knockoff versions of the drugs in the country.

Merck-partnered Euroscreen raises €16M to support IND filing

Euroscreen has topped up its bank balance to support the globalization of its clinical trial program. The €16 million ($18 million) round will allow the G-protein coupled receptor specialist to file an IND and advance ongoing Phase II trials of its lead candidate in women's health diseases.